APA (7th ed.) Citation

Jungwirth, G., Paul, A., Wöllner, A., Warta, R., Cao, J., Fermi, V., . . . Herold-Mende, C. (2026). Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors. npj precision oncology, 10, . https://doi.org/10.1038/s41698-026-01552-5

Chicago Style (17th ed.) Citation

Jungwirth, Gerhard, et al. "Automated and Personalized Glioblastoma Tumor Organoid Drug Screening Platform Exposes Sensitivity to Proteasome and HDAC Inhibitors." Npj Precision Oncology 10 (2026). https://doi.org/10.1038/s41698-026-01552-5.

MLA (9th ed.) Citation

Jungwirth, Gerhard, et al. "Automated and Personalized Glioblastoma Tumor Organoid Drug Screening Platform Exposes Sensitivity to Proteasome and HDAC Inhibitors." Npj Precision Oncology, vol. 10, 2026, https://doi.org/10.1038/s41698-026-01552-5.